PAREXEL International Corporation (NASDAQ: PRXL)
Overview
PAREXEL International excels in biopharmaceutical development services. A top contract research organization (CRO), the firm counts among its clients some of the world's largest drug, biotech, and medical device firms. Its Clinical Research Services segment's offerings include clinical trial and data management, study design, patient recruitment, biostatistical analysis, clinical pharmacology, and industry training and publishing. PAREXEL Consulting and Medical Communications Services handles the non-clinical aspects of drug development, regulatory affairs, and new product launches. Its Perceptive Informatics unit offers information technology systems and services that help manage clinical trials.
Sample Overview & HistoryKey Numbers from Hoover's UK
Key financials for PAREXEL International Corporation (NASDAQ: PRXL)
| Company Type | Public (NASDAQ: PRXL) |
|---|---|
| Fiscal Year-End | June |
| 2011 Sales (mil.) | £887.9 |
| 1-Year Sales Growth | 6.5% |
| 2011 Net Income (mil.) | £30.5 |
| 1-Year Net Income Growth | 17.4% |
| 2011 Employees | 10,550 |
| 1-Year Employee Growth | 8.5% |
Key People from Hoover's UK
Key people and executives for PAREXEL International Corporation (NASDAQ: PRXL)
| Chairman and CEO | Josef H. von Rickenbach (Subscribers see complete biographies -- view sample)
|
|---|---|
| COO; President Clinical Research Services | Mark A. Goldberg |
| SVP and CFO | James F. Winschel Jr. |
Top Competitors from Hoover's UK
Top competitors of PAREXEL International Corporation (NASDAQ: PRXL)
There are 15 competitors for PAREXEL; see more.Industry Information from Hoover's UK
First Research Industry Profiles Extensive Industry Intelligence
Hoover's Industries
More Industry InformationSubsidiaries/Affiliates Covered By Hoover's UK
Subsidiaries/affiliates of PAREXEL International Corporation (NASDAQ: PRXL)
Rankings from Hoover's UK
See how PAREXEL International Corporation (NASDAQ: PRXL) ranks in standard industry listings such as Fortune 500, S&P 500, and Dow Jones
- S&P 600
- Russell 2000 (June 2011)

